跳至主要内容
临床试验/KCT0002935
KCT0002935已完成未知

Ticagrelor Monotherapy after 3 months in the Patients treated with New Generation Sirolimus-Eluting Stents for Acute Coronary Syndrome

Yonsei University Health System, Severance Hospital0 个研究点目标入组 3,056 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
3,056

研究概览

简要总结

Among patients who treated with DES for acute coronary syndrome, the incidence of net adverse clinical event was significantly lower in those with the ticagrelor monotherapy after 3-month DAPT than those with the currently recommended ticagrelor-based 12-month DAPT, mainly driven by lower major bleeding.

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19(Year) 至 79(Year)(—)
性别
All

入选标准

  • 1. Patients = 19 years old 2. Patients who received new
  • generation sirolimus-eluting (Osiro®) stent implantation for treating ACS,
  • including acute MI and unstable angina 3. Patients without significant clinical
  • events such as MI, stent thrombosis or revascularization until 3 months after
  • PCI 4. Provision of informed consent

排除标准

  • 1. Age> 80 years 2. Increased risk of bleeding, anemia,
  • thrombocytopenia 3. A need for oral anticoagulation therapy 4. Pregnant women or
  • women with potential childbearing 5. Life expectancy < 1 year 6. Patients
  • receiving a potent CYP3A4 inhibitor (eg, ketoconazole, clarithromycin,
  • napjodone, ritonavir, atazanavir) 7. Patients with a history of intracranial
  • bleeding 8. Patients with moderate to severe hepatic impairment 9. Patients at
  • risk of bradykinesia (based on licensing and clinical
  • literature)

研究者

相似试验